REPL
Replimune Group Inc
NASDAQ: REPL · HEALTHCARE · BIOTECHNOLOGY
$4.09
-4.05% today
Updated 2026-06-05
Market cap
$699.39M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.44
Dividend yield
—
52W range
$2 – $13
Volume
8.8M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.5
Quality
C+3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$4.67
+14.11%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy0 Buy6 Hold2 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.36x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -1.18 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-66.09M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-118.04M | $-174.28M | $-215.79M | $-247.30M | $-70.93M |
| EPS | — | — | — | — | $-3.44 |
| Free cash flow | $-84.52M | $-130.32M | $-191.13M | $-198.94M | $-66.09M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-18 | XYNOS, KONSTANTINOS | Sale | 14,023 | $5.08 |
| 2026-05-18 | SCHWENDENMAN, ANDREW | Sale | 7,894 | $5.08 |
| 2026-05-18 | SARCHI, CHRISTOPHER | Sale | 8,626 | $5.08 |
Peer comparison
Smart narrative
Replimune Group Inc trades at $4.09. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -1.18, it sits in the distress.
Frequently asked questions
What is Replimune Group Inc's stock price?
Replimune Group Inc (REPL) trades at $4.09.
Is Replimune Group Inc overvalued?
Replimune Group Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Replimune Group Inc (REPL)?
The 12-month analyst consensus target is $4.67, about 14.1% above the current $4.09. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Replimune Group Inc's Altman Z-Score is -1.18, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-149.55%
Beta0.91
50D MA$5.03
200D MA$6.93
Shares out0.08B
Float0.06B
Short ratio—
Avg volume8.8M
Performance
1 week+0.00%
1 month+92.09%
3 months+32.63%
YTD-2.57%
1 year—
3 years—
5 years—